Catalyst Pharmaceuticals Inc. (CPRX), which achieved over 23% revenue growth in 2024, expects continued growth in 2025, reflecting confidence in its ongoing momentum.
The company's marketed drugs include Firdapse, which is approved for the treatment of adult patients with Lambert-Eaton myasthenic syndrome, the anti-epileptic drug Fycompa, and the Duchenne muscular dystrophy drug Agamree.
For the full year of 2024, the company reported a total revenue of approximately $491.7 million, compared to $398.2 million in 2023, reflecting a year-over-year increase of around 23.4%. This includes both product sales and revenue from licenses and other sources.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.